Penumbra is evaluating its differentiated computer-assisted vacuum thrombectomy technology (CAVT) for stroke treatment, gaining traction in the venous setting via the Storm-PE trial.
2 reports, 2 independent
Updated Aug 26
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Penumbra is evaluating its differentiated computer-assisted vacuum thrombectomy technology (CAVT) for stroke treatment, gaining traction in the venous setting via the Storm-PE trial.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Penumbra is advancing its product line with new data from the Storm-PE trial for stroke treatment.1 source
Successful rollout and adoption of CAVT technology in the U.S. thrombectomy market.1 source
Keep exploring
The entities involved
-
Penumbra
medical device company in Alameda, California
Coverage
Newest first; wire copies grouped- Insider MonkeyPenumbra, Inc. (PEN): A Bull Case Theory We came across a bullish thesis on Penumbra, Inc. on Stock Analysis Compilation’s Substack. In this article, we will summarize the bulls’ thesis on PENz. Penu
- StockStoryPEN Q2 Deep Dive: Sales Force Expansion and Clinical Milestones Drive Outperformance Medical device company Penumbra (NYSE:PEN) reported Q2 CY2025 results beating Wall Street’s revenue expectations ,